JPWO2021232019A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021232019A5 JPWO2021232019A5 JP2022568780A JP2022568780A JPWO2021232019A5 JP WO2021232019 A5 JPWO2021232019 A5 JP WO2021232019A5 JP 2022568780 A JP2022568780 A JP 2022568780A JP 2022568780 A JP2022568780 A JP 2022568780A JP WO2021232019 A5 JPWO2021232019 A5 JP WO2021232019A5
- Authority
- JP
- Japan
- Prior art keywords
- sting agonist
- inhibitor
- patient
- use according
- ctla4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940044665 STING agonist Drugs 0.000 claims 33
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 15
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 15
- 239000012270 PD-1 inhibitor Substances 0.000 claims 7
- 239000012668 PD-1-inhibitor Substances 0.000 claims 7
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 7
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 7
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 230000006023 anti-tumor response Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025905P | 2020-05-15 | 2020-05-15 | |
| US63/025,905 | 2020-05-15 | ||
| US202063091874P | 2020-10-14 | 2020-10-14 | |
| US63/091,874 | 2020-10-14 | ||
| PCT/US2021/032800 WO2021232019A1 (en) | 2020-05-15 | 2021-05-17 | Sting agonist combination treatments with immune checkpoint inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533111A JP2023533111A (ja) | 2023-08-02 |
| JPWO2021232019A5 true JPWO2021232019A5 (zh) | 2024-05-24 |
Family
ID=76306053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568780A Pending JP2023533111A (ja) | 2020-05-15 | 2021-05-17 | 免疫チェックポイント阻害剤とのｓｔｉｎｇアゴニスト併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210380695A1 (zh) |
| EP (1) | EP4149457A1 (zh) |
| JP (1) | JP2023533111A (zh) |
| KR (1) | KR20230011324A (zh) |
| CN (1) | CN115803032A (zh) |
| AU (1) | AU2021273508A1 (zh) |
| CA (1) | CA3178464A1 (zh) |
| IL (1) | IL298148A (zh) |
| MX (1) | MX2022014110A (zh) |
| WO (1) | WO2021232019A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114940679B (zh) * | 2022-05-23 | 2023-05-16 | 浙江大学医学院附属第四医院 | Sting激动剂前药化合物及其制备方法和应用 |
| WO2024064724A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Compositions and methods for treating cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| EP3546473A1 (en) | 2014-12-16 | 2019-10-02 | Kayla Therapeutics | Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| WO2016144564A2 (en) * | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| MA42608A (fr) | 2015-08-13 | 2018-06-20 | Merck Sharp & Dohme | Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron) |
| WO2017100305A2 (en) | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition of antibody construct-agonist conjugates and methods of use thereof |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| CN114230625A (zh) | 2016-03-18 | 2022-03-25 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| RU2019122602A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака |
| WO2018118665A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| US11701364B2 (en) | 2018-02-21 | 2023-07-18 | The Scripps Research Institute | Agonists of stimulator of interferon genes sting |
| AU2020366354A1 (en) * | 2019-10-14 | 2022-03-17 | Immunesensor Therapeutics, Inc. | Methods of treating cancer with a sting agonist |
-
2021
- 2021-05-17 MX MX2022014110A patent/MX2022014110A/es unknown
- 2021-05-17 AU AU2021273508A patent/AU2021273508A1/en active Pending
- 2021-05-17 US US17/322,827 patent/US20210380695A1/en active Pending
- 2021-05-17 CN CN202180046447.0A patent/CN115803032A/zh active Pending
- 2021-05-17 JP JP2022568780A patent/JP2023533111A/ja active Pending
- 2021-05-17 IL IL298148A patent/IL298148A/en unknown
- 2021-05-17 WO PCT/US2021/032800 patent/WO2021232019A1/en active Application Filing
- 2021-05-17 CA CA3178464A patent/CA3178464A1/en active Pending
- 2021-05-17 KR KR1020227042332A patent/KR20230011324A/ko active Search and Examination
- 2021-05-17 EP EP21730772.7A patent/EP4149457A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ager et al. | Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity | |
| Theiss et al. | Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | |
| Aglietta et al. | A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer | |
| Awad et al. | Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury | |
| Chin et al. | Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C | |
| Byrne et al. | CSF-1R–dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy | |
| Garnock-Jones | Secukinumab: a review in moderate to severe plaque psoriasis | |
| Marinelli et al. | Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study | |
| RU2011104955A (ru) | Композиции антител | |
| US20220041745A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses | |
| Flowers et al. | Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes | |
| Bravo et al. | Vimentin and heat shock protein expression are induced in the kidney by angiotensin and by nitric oxide inhibition | |
| US20230277660A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib, Mephalan and Prednisone | |
| US20200308284A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone | |
| JP2021500336A5 (zh) | ||
| JP2019218359A (ja) | Ｇｄ２陽性がんを処置するための製剤および方法 | |
| US20230330224A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone | |
| US20230295333A1 (en) | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone | |
| Schwartz et al. | Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)–paclitaxel or docetaxel adjuvant chemotherapy in breast cancer | |
| Keiser et al. | Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients | |
| Su et al. | Successful therapy for myocarditis concomitant with complete heart block after pembrolizumab treatment for head and neck squamous cell carcinoma: A case report with literature review | |
| JPWO2021232019A5 (zh) | ||
| Mimouni et al. | Pemphigus | |
| MX2022014110A (es) | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. | |
| Nicolas et al. | Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a |